Nakashima S, Kakugawa T, Motomura H, et al. Development of imatinibmesylate-induced interstitial lung disease 2 weeks after discontinuation of the treatment: a case report. Multidiscip Respir Med. 2012;7. doi:10.4081/mrm.2012.635